Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
BULLISH SIGNAL DETECTED
██.█% Sign up free to reveal

Bio-Techne Corp (TECH) AI Forecast

Our AI detected a significant signal for Bio-Techne Corp. Create a free account to see the exact price target.

✓ Free account • ✓ 30-day free trial

$TECH Bullish Signal Full forecast available
Sign Up Free

Bio-Techne Corp (TECH) Stock Forecast 2025

Bio-Techne Corp (TECH) AI Stock Price Forecast & Investment Analysis

Bio-Techne Corp Stock Price Chart and Technical Analysis

Loading chart...

Bio-Techne Corp (TECH) - Comprehensive Stock Analysis & Investment Research

Deep dive into Bio-Techne Corp's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on March 10, 2026, 2:26 p.m. (UTC)

Bio-Techne Corp Investment Summary

When evaluating whether Bio-Techne Corp (TECH) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Bio-Techne Corp (TECH) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $8 billion, the company is a mid-cap stock that typically offers a balance between growth potential and established business operations.

Financial Performance Analysis

Our comprehensive financial analysis covers Bio-Techne Corp's revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Bio-Techne Corp along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Bio-Techne Corp is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Bio-Techne Corp

Sign Up Free
Corporate Identity

Bio-Techne Corp (Stock Symbol: TECH) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Bio-Techne Corp's leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Bio-Techne Corp...

Sector & Industry Analysis

In-depth sector dynamics and industry context for Bio-Techne Corp...

Unlock Full Company Profile

Get complete details about Bio-Techne Corp

Sign Up Free
Revenue & Growth Analysis

Bio-Techne Corp generates annual revenues of $1 billion , indicating a well-established business with proven market demand.

Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Bio-Techne Corp...

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Bio-Techne Corp...

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Bio-Techne Corp...

Unlock Financial Analysis

Get complete financial metrics for Bio-Techne Corp

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Bio-Techne Corp's AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Bio-Techne Corp strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a mid-cap company, it occupies an attractive position balancing growth potential with established operations. Mid-caps often represent the 'sweet spot' for investors seeking companies that have proven their business models but still have meaningful runway for expansion. These companies are large enough to have competitive advantages but nimble enough to adapt quickly to market changes.

Industry Competitive Landscape

Bio-Techne Corp competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency
Margin & Pricing Power Analysis

The company maintains a 77.6% gross margin which reflects exceptional pricing power and/or an asset-light business model. Gross margins at this level are typically seen in software, pharmaceuticals, or luxury goods companies where the cost of incremental production is minimal relative to selling prices. Such margins indicate significant competitive advantages protecting the company from price-based competition.

Operating margin of 56.5% demonstrates how efficiently the company converts revenues into operating profits after accounting for all operating expenses including research and development, sales and marketing, and general administrative costs. This strong operating margin indicates excellent cost control and efficient organizational structure relative to the revenue base.

Financial Strength & Leverage

Bio-Techne Corp (TECH) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Bio-Techne Corp stock analysis.

Deep dive into Bio-Techne Corp's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Bio-Techne Corp stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Bio-Techne Corp: With a P/E ratio of 103.58, the market highly values future growth prospects.

P/E Ratio 103.58x
P/B Ratio 4.18x
Market Cap $8.40B
Dividend Yield 0.59%
Book Value/Share $12.90
Revenue/Share $7.80
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Bio-Techne Corp converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Bio-Techne Corp:

Gross Margin 77.6%
Operating Margin 56.5%
Net Margin 38.8%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Bio-Techne Corp's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Bio-Techne Corp:

Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Bio-Techne Corp's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Bio-Techne Corp:

Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Bio-Techne Corp uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Bio-Techne Corp:

Understanding Financial Statement Data

What these metrics mean: Key figures from Bio-Techne Corp's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Bio-Techne Corp: With annual revenue of $1215M, Bio-Techne Corp operates at significant scale.

Income Statement
Total Revenue $1.22B
Operating Income $153M
Net Income $105M
Cost of Goods Sold $61M
Balance Sheet Highlights (% Of Assets)
Dividend & Shareholder Information
Payout Ratio 0.3%
Shares Outstanding 156M
Growth Metrics (YoY)
EPS Growth 1.3%

Latest Bio-Techne Corp Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Bio-Techne Corp (TECH) stock price and investment outlook.

📰 We are currently updating our news feed for Bio-Techne Corp. Check back soon for the latest market analysis and company updates.

Bio-Techne Corp Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Bio-Techne Corp against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
Acumen Pharmaceuticals, Inc. ABOS ██% $190M -1.9x 2.0x
Abpro Holdings, Inc. ABP ██% $300K x 0.0x
Arcellx, Inc. ACLX ██% $6.63B -74.1x 16.5x
Alpha Cognition Inc. ACOG ██% $126M x 3.7x
Adaptimmune Therapeutics Plc ADAP ██% $77M -13.2x -11.8x
Adma Biologics, Inc. ADMA ██% $3.66B 24.9x 7.7x
Adaptive Biotechnologies Corp ADPT ██% $2.29B -4.6x 10.4x
Adverum Biotechnologies, Inc. ADVM ██% $95M -1.8x 2.2x
Agenus Inc AGEN ██% $103M -0.5x 30.3x
Agentix Corp. AGTX ██% $2M x 296.8x
Aim Immunotech Inc. AIM ██% $3M -0.5x 1.1x
Aim Immunotech Inc. AIMI ██% $1M x x
Alector, Inc. ALEC ██% $242M -1.2x 7.9x
Aligos Therapeutics, Inc. ALGS ██% $43M -19.2x 0.8x
Allogene Therapeutics, Inc. ALLO ██% $558M -1.4x 1.8x
Alvotech ALVO ██% $1.21B x x
Amgen Inc AMGN ██% $203.11B 26.3x 23.5x
Apogee Therapeutics, Inc. APGE ██% $5.00B -20.5x 4.3x
Aptose Biosciences Inc. APTOF ██% $4M x x
Argenx Se ARGX ██% $43.61B x x
Armata Pharmaceuticals, Inc. ARMP ██% $423M -1.0x 22.1x
Artiva Biotherapeutics, Inc. ARTV ██% $140M x 1.1x
Leonabio, Inc. ATHA ██% $23M -0.2x 0.9x
Atara Biotherapeutics, Inc. ATRA ██% $48M 2.1x 6.5x
Atyr Pharma Inc ATYR ██% $88M -3.6x 1.3x
Aura Biosciences, Inc. AURA ██% $357M -4.9x 2.3x
Autolus Therapeutics Plc AUTL ██% $431M x 1.6x
Anavex Life Sciences Corp. AVXL ██% $431M -17.3x 3.4x
Bioatla, Inc. BCAB ██% $14M -1.1x 25.7x
Biocardia, Inc. BCDA ██% $14M -0.6x 5.2x
Brainstorm Cell Therapeutics Inc. BCLI ██% $8M -4.9x 5.8x
Biocryst Pharmaceuticals Inc BCRX ██% $2.13B 8.1x 63.2x
Black Diamond Therapeutics, Inc. BDTX ██% $122M 5.7x 1.0x
Beam Therapeutics Inc. BEAM ██% $2.70B -12.6x 2.2x
Biogen Inc. BIIB ██% $27.14B 21.0x 1.8x
Biontech Se BNTX ██% $25.64B x x
Cabaletta Bio, Inc. CABA ██% $305M -1.6x 2.2x
Candel Therapeutics, Inc. CADL ██% $376M -4.6x 4.7x
C4 Therapeutics, Inc. CCCC ██% $232M -2.6x 1.5x
Cidara Therapeutics, Inc. CDTX ██% $6.49B -1.0x 15.4x
Creative Medical Technology Holdings, Inc. CELZ ██% $7M -3.4x 1.2x
Cero Therapeutics Holdings, Inc. CERO ██% $720K x -196.2x
Cullinan Therapeutics, Inc. CGEM ██% $904M -4.1x 2.0x
Compugen Ltd CGEN ██% $203M x 2.0x
Cg Oncology, Inc. CGON ██% $4.95B x 6.6x
Cognition Therapeutics Inc CGTX ██% $95M -0.5x 2.6x
Coherus Oncology, Inc. CHRS ██% $288M 1.7x 4.7x
Calidi Biotherapeutics, Inc. CLDI ██% $3M -0.9x 0.4x
Cellectis S.A. CLLS ██% $400M x x
Compass Therapeutics, Inc. CMPX ██% $967M -4.8x 4.9x
Mosaic Immunoengineering Inc. CPMV ██% $4M x 14.6x
Caribou Biosciences, Inc. CRBU ██% $142M -1.5x 1.0x
Cardiff Oncology, Inc. CRDF ██% $133M -4.0x 2.9x
Cardiol Therapeutics Inc. CRDL ██% $109M x x
Curis Inc CRIS ██% $13M -0.3x 1.4x
Crispr Therapeutics Ag CRSP ██% $5.64B -12.1x 2.9x
Champions Oncology, Inc. CSBR ██% $83M 33.3x 19.9x
Cel Sci Corp CVM ██% $33M -0.9x 2.9x
Dbv Technologies S.A. DBVT ██% $1.29B -3.3x 24.3x
Dbv Technologies S.A. DBVTF ██% $10K x 0.0x
Ginkgo Bioworks Holdings, Inc. DNA ██% $385M -13.9x 0.8x
Denali Therapeutics Inc. DNLI ██% $3.33B -8.7x 3.3x
Precision Biosciences Inc DTIL ██% $113M -2.2x 6.8x
Dyadic International Inc DYAI ██% $29M -7.3x 11.1x
Editas Medicine, Inc. EDIT ██% $227M -0.8x 8.3x
Elutia Inc. ELUT ██% $48M -1.4x 7.3x
Engene Holdings Inc. ENGN ██% $472M 3.7x 1.7x
Entera Bio Ltd. ENTX ██% $63M 8.5x 4.2x
Enzon Pharmaceuticals, Inc. ENZN ██% $4M x 10.3x
Estrella Immunopharma, Inc. ESLA ██% $47M -3.1x 327.6x
Evaxion A/S EVAX ██% $26M x x
Exelixis, Inc. EXEL ██% $11.12B 14.2x 5.2x
Exozymes Inc. EXOZ ██% $61M x 11.4x
Fate Therapeutics Inc FATE ██% $153M -1.3x 0.7x
4d Molecular Therapeutics, Inc. FDMT ██% $499M -3.0x 1.4x
Fennec Pharmaceuticals Inc. FENC ██% $263M 1758.3x 87.3x
Finch Therapeutics Group, Inc. FNCH ██% $21M -0.1x 1.5x
Futuretech Ii Acquisition Corp. FTII ██% $52M x -0.7x
Futuretech Ii Acquisition Corp. FTIIU ██% $14M x -0.8x
Gilead Sciences, Inc. GILD ██% $181.97B 21.4x 8.0x
Monte Rosa Therapeutics, Inc. GLUE ██% $1.35B 64.6x 5.5x
Genenta Science S.P.A. GNTA ██% $20M x 1.6x
Green Planet Bio Engineering Co. Ltd. GPLB ██% $340K x x
Halozyme Therapeutics, Inc. HALO ██% $8.03B 25.3x 164.4x
Humacyte, Inc. HUMA ██% $215M -3.3x 53.1x
Immunitybio, Inc. IBRX ██% $8.55B -3.6x 72.8x
Inhibikase Therapeutics, Inc. IKT ██% $229M -1.0x 3.1x
Immunocore Holdings Plc IMCR ██% $1.69B x 4.5x
Immatics N.V. IMTX ██% $1.34B x x
Immunovant, Inc. IMVT ██% $5.37B -14.5x 5.5x
In8bio, Inc. INAB ██% $17M x 1.3x
Inhibrx Biosciences, Inc. INBX ██% $1.04B -6.8x 28.3x
Mink Therapeutics, Inc. INKT ██% $49M -1.5x 7.3x
Inmune Bio, Inc. INMB ██% $35M -2.5x 1.4x
Intensity Therapeutics, Inc. INTS ██% $20M -2.2x 2.7x
Iovance Biotherapeutics, Inc. IOVA ██% $2.23B -4.5x 3.2x
Century Therapeutics, Inc. IPSC ██% $254M -0.7x 1.4x
Invivyd, Inc. IVVD ██% $533M -0.4x 2.2x
Jasper Therapeutics, Inc. JSPR ██% $37M -3.2x 3.2x
Kalaris Therapeutics, Inc. KLRS ██% $184M x 4.4x
Klotho Neurosciences, Inc. KLTO ██% $51M x 5.1x
Kodiak Sciences Inc. KOD ██% $1.52B -2.5x 64.1x
Krystal Biotech, Inc. KRYS ██% $7.55B 36.9x 6.2x
Kymera Therapeutics, Inc. KYMR ██% $6.92B -17.8x 4.4x
Kyverna Therapeutics, Inc. KYTX ██% $501M x 3.3x
Ladrx Corp LADX ██% $0.00M x 0.0x
Lineage Cell Therapeutics, Inc. LCTX ██% $430M -4.7x 9.7x
Lenz Therapeutics, Inc. LENZ ██% $352M -6.7x 1.8x
Liminatus Pharma, Inc. LIMN ██% $9M x x
Lexeo Therapeutics, Inc. LXEO ██% $500M -0.4x 4.1x
Maze Therapeutics, Inc. MAZE ██% $2.17B x 5.7x
Mesoblast Ltd MESO ██% $2.05B x x
Meiragtx Holdings Plc MGTX ██% $563M -3.4x 190.3x
Metagenomi Therapeutics, Inc. MGX ██% $60M x 0.4x
Molecular Partners Ag MOLN ██% $202M x x
Moderna, Inc. MRNA ██% $21.96B -3.2x 2.5x
Neurocrine Biosciences Inc NBIX ██% $13.01B 27.2x 4.0x
Nkgen Biotech, Inc. NKGN ██% $2M -0.1x -0.2x
Neumora Therapeutics, Inc. NMRA ██% $488M -3.9x 3.7x
Novavax Inc NVAX ██% $1.62B 3.7x 43.1x
Ocugen, Inc. OCGN ██% $559M -4.3x 158.3x
Outlook Therapeutics, Inc. OTLK ██% $37M -0.2x 3.6x
Palisade Bio, Inc. PALI ██% $263M -0.2x 81.8x
Passage Bio, Inc. PASG ██% $28M -0.6x 1.5x
Vaxcyte, Inc. PCVX ██% $7.62B -20.4x 2.8x
Biomx Inc. PHGE ██% $11M 1.5x 1.1x
Pluri Inc. PLUR ██% $33M -1.4x 340.9x
Protalix Biotherapeutics, Inc. PLX ██% $225M 41.8x 4.3x
Pharmacyte Biotech, Inc. PMCB ██% $8M 0.3x 0.2x
Prime Medicine, Inc. PRME ██% $791M -1.5x 6.5x
Prokidney Corp. PROK ██% $692M x 0.0x
Qiagen N.V. QGEN ██% $9.90B x 2.8x
Quince Therapeutics, Inc. QNCX ██% $6M -1.7x 5.3x
Qrons Inc. QRON ██% $150K x x
Replimune Group, Inc. REPL ██% $643M -3.8x 3.1x
Repligen Corp RGEN ██% $6.76B 138.2x 3.2x
Regenxbio Inc. RGNX ██% $440M -1.8x 4.3x
Relay Therapeutics, Inc. RLAY ██% $1.70B -2.0x 3.0x
Revolution Medicines, Inc. RVMD ██% $19.38B -11.1x 11.9x
Recursion Pharmaceuticals, Inc. RXRX ██% $1.83B -4.7x 1.6x
Sab Biotherapeutics, Inc. SABS ██% $180M 9.6x 1.1x
Sana Biotechnology, Inc. SANA ██% $840M -2.1x 5.2x
Scilex Holding Co SCLX ██% $58M -0.4x 5.5x
Scinai Immunotherapeutics Ltd. SCNI ██% $3M -287.8x 0.4x
Sangamo Therapeutics, Inc SGMO ██% $141M -1.6x 22.6x
Solid Biosciences Inc. SLDB ██% $526M -0.9x 2.4x
Silexion Therapeutics Corp SLXN ██% $6M x 0.8x
Senti Biosciences, Inc. SNTI ██% $25M -1.1x 3.1x
Scholar Rock Holding Corp SRRK ██% $5.00B -18.5x 20.4x
Surrozen, Inc./De SRZN ██% $232M -0.5x 4.9x
Sutro Biopharma, Inc. STRO ██% $414M -1.0x 9.3x
Protara Therapeutics, Inc. TARA ██% $316M -2.1x 2.4x
Tarsus Pharmaceuticals, Inc. TARS ██% $3.12B -12.4x 9.1x
Tc Biopharm (Holdings) Plc TCBPY ██% $110K x 0.1x
Tscan Therapeutics, Inc. TCRX ██% $60M -4.6x 0.4x
Bio-Techne Corp TECH ██% $8.40B 103.6x 4.2x
Tectonic Therapeutic, Inc. TECX ██% $451M -8.9x 1.8x
Instil Bio, Inc. TIL ██% $60M -1.1x 0.5x
Tenaya Therapeutics, Inc. TNYA ██% $122M -2.5x 1.5x
Tourmaline Bio, Inc. TRML ██% $1.23B -3.5x 4.8x
Taysha Gene Therapies, Inc. TSHA ██% $1.25B -3.0x 5.7x
Titan Pharmaceuticals Inc TTNP ██% $6M -0.5x 2.2x
Tevogen Bio Holdings Inc. TVGN ██% $30M x 2178.2x
Twist Bioscience Corp TWST ██% $2.88B -12.6x 6.3x
Voyager Acquisition Corp./Cayman Islands VACH ██% $339M 33.2x 0.0x
Voyager Acquisition Corp./Cayman Islands VACHU ██% $68M 6.7x 0.0x
Valneva Se VALN ██% $914M x x
Vericel Corp VCEL ██% $1.75B 106.2x 5.0x
Vir Biotechnology, Inc. VIR ██% $1.50B -2.0x 1.9x
Vivosim Labs, Inc. VIVS ██% $5M x 1.1x
Vor Biopharma Inc. VOR ██% $643M -0.6x 9.7x
Vaxart, Inc. VXRT ██% $169M -0.9x 6.3x
Voyager Therapeutics, Inc. VYGR ██% $216M 570.6x 1.0x
Windtree Therapeutics Inc /De/ WINT ██% $440K -0.4x 0.1x
X4 Pharmaceuticals, Inc XFOR ██% $290M 6.4x 4.7x
Zeo Scientifix, Inc. ZEOX ██% $16M x 23.0x
Zivo Bioscience, Inc. ZIVO ██% $36M -31.3x 23.6x
Zura Bio Ltd ZURA ██% $661M x 6.1x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Bio-Techne Corp Stock Forecast

How accurate are Bio-Techne Corp stock predictions?

Our AI model shows a -6% Spearman correlation coefficient for TECH predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Bio-Techne Corp stock price forecasts?

Our analysis considers Bio-Techne Corp's financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Bio-Techne Corp a good investment in 2025?

Based on our AI analysis, Bio-Techne Corp shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Bio-Techne Corp forecasts updated?

Bio-Techne Corp stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

My Portfolio

Investment Dashboard

Loading your portfolio...